Mounjaro for Diabetes Only: What UK Guidance Actually Says

How tirzepatide's two UK licences came about

Tirzepatide was developed initially as a diabetes medicine. It works by activating two gut-hormone receptors simultaneously (GIP and GLP-1) which together slow gastric emptying, improve insulin sensitivity, and reduce appetite. The MHRA granted Eli Lilly a UK licence for type 2 diabetes first, and a separate UK licence for weight management followed as the clinical evidence base expanded. The two licences coexist; neither cancels the other. Our full Mounjaro overview sets out what each licence covers in more detail.

NICE appraised tirzepatide for weight management in December 2024, publishing Technology Appraisal TA1026. That appraisal focused on adults with obesity, including those who also have type 2 diabetes, and recommended tirzepatide for NHS use in England subject to phased eligibility criteria. Crucially, having type 2 diabetes does not exclude someone from the weight-management licence, and you can read more about how Mounjaro applies to type 2 diabetes including its role as one of the qualifying weight-related conditions for people with a BMI between 27 and 29.9.

Where things become clinically important is the interaction between tirzepatide and existing diabetes medicines. The prescriber's job is to weigh those interactions carefully, adjust regimens where needed, and monitor you appropriately. That clinical layer is the reason a thorough assessment matters so much here.

What the trial evidence shows for people with type 2 diabetes specifically

The clearest evidence for this group comes from the SURMOUNT-2 trial, which enrolled adults with obesity or overweight who also had type 2 diabetes. Published data showed average body-weight reductions of around 12–15% at 72 weeks depending on dose, alongside clinically meaningful reductions in HbA1c. The SURMOUNT-1 trial in the New England Journal of Medicine provides the comparable evidence in people without diabetes, where average reductions reached around 20–21% at 15mg over 72 weeks.

The gap between those two figures reflects a well-understood pattern with GLP-1 class medicines: people with type 2 diabetes tend to lose somewhat less weight on average, in part because of the metabolic effects of the condition itself and some of the medicines used alongside it. That does not mean treatment is ineffective, the reductions in SURMOUNT-2 remain substantial by any clinical standard. It does mean that realistic expectations and individualised clinical review are both essential.

If you are trying to understand whether your HbA1c, existing diabetes medication, or diabetes-related complications change the risk-benefit calculation, that is exactly the conversation a prescriber is there to have with you. You can read more about Mounjaro's use in type 2 diabetes on a dedicated page, including how titration is typically managed alongside diabetes care.

Drug interactions and safety considerations when diabetes medicines are involved

We recognise that if you are already managing diabetes and now considering a weight-management medicine, the stakes feel higher than they might for someone without an existing treatment regimen. That concern is well-founded, and it is one the prescribing process is specifically designed to address.

The most significant interaction to know about is with insulin and sulfonylureas (such as gliclazide or glibenclamide). Tirzepatide lowers blood glucose, and when combined with these medicines the risk of hypoglycaemia increases. Current clinical guidance recommends reducing the dose of those medicines when starting tirzepatide, with careful monitoring. The NHS tirzepatide information page summarises this and lists other medicines that warrant attention.

Metformin, the most commonly prescribed first-line diabetes medicine in the UK, does not carry the same low-blood-sugar risk when combined with tirzepatide, and the two are frequently used together. SGLT-2 inhibitors and DPP-4 inhibitors each have their own considerations, which a prescriber familiar with your full medicines list will work through.

Pancreatitis is a known but infrequent risk with GLP-1 class medicines. The MHRA issued a Drug Safety Update in January 2026 highlighting this and advising that severe, persistent stomach pain (particularly if it reaches the back) warrants prompt medical attention. Anyone with a history of pancreatitis or certain gallbladder conditions should discuss this with a specialist before starting. Explore whether Mounjaro is a suitable option if you have diabetes for a fuller look at who tends to benefit most.

Who to involve in the decision and what happens next

If you have type 2 diabetes managed by a hospital diabetes team or specialist, their input is important before any changes to your medicines. Your GP should be informed as a matter of course, and our page on how Mounjaro relates to diabetes management explains the broader context, with GP notification also a standard part of our clinical process, in line with GPhC guidance. If your diabetes is well-controlled and managed in primary care, your GP practice is often the right first port of call alongside a prescribing service.

For people who do not meet the current NHS thresholds, or who would prefer not to wait, a private regulated prescriber can assess suitability and, where appropriate, initiate treatment. The assessment will cover your current diabetes medicines, your HbA1c, your BMI, and any other relevant health information. Understanding the cost context is useful background if you are considering the private route.

Treatment decisions are never made by an algorithm at nume. A GPhC-registered Independent Prescriber reads your consultation answers the same day and makes the clinical call. If you would like that assessment, speak to our prescribers through a free consultation, there is no obligation, and clinical suitability is always the deciding factor.